Secondary Stock Offerings
By The Online Investor Staff, updated Sat., Jul. 2, 12:50 PM
| This Slide: #1 of 25 |
Slide #1. Verrica Pharmaceuticals Inc. — Secondary Offering
Company:
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)
Date announced:
6/29/2022
Shares Offered:
12,000,000
Date of Pricing:
6/29/2022
Price Per Share:
$2.10
Secondary Offering Details:
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by Verrica. Verrica also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. -updated 6/29- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of its underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $2.10 per share. In addition, Verrica has granted to the underwriter a 30-day option to purchase up to 1,800,000 additional shares of common stock at the public offering price, less the underwriting discount. The gross proceeds from the offering to Verrica are expected to be approximately $25.2 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriter's option. The offering is expected to close on or about July 5, 2022, subject to customary closing conditions.
Verrica Pharmaceuticals is a dermatology therapeutics company focused on the development and commercialization of treatments for people living with skin diseases. Co.'s primary product candidate, VP-102, is a proprietary drug-device combination of its topical solution of cantharidin, a naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. Co. is initially developing VP-102 for the treatment of molluscum contagiosum, a highly contagious and primarily pediatric viral skin disease, external genital warts and common warts.
Open the VRCA Page at The Online Investor »
|
|||||||||||||||||||||
Open the VRCA Page at The Online Investor (in a new window) »
List of Secondary Stock Offerings in this Slideshow:
4/14/2022:
Company: Zhihu Inc. (ZH)
Shares Offered: 26,000,000
More: offering details »
4/21/2022:
Company: Soluna Holdings, Inc. (SLNH)
Shares Offered: 525,714
More: offering details »
4/25/2022:
Company: Nkarta, Inc. (NKTX)
Shares Offered: 13,333,334
More: offering details »
4/29/2022:
Company: Sono Group N.V. (SEV)
Shares Offered: 10,000,000
More: offering details »
5/2/2022:
Company: Tarsus Pharmaceuticals, Inc. (TARS)
Shares Offered: 5,600,000
More: offering details »
5/3/2022:
Company: Freshpet, Inc. (FRPT)
Shares Offered: 4,320,988
More: offering details »
5/5/2022:
Company: Digital Brands Group, Inc. (DBGI)
Shares Offered: 37,389,800
More: offering details »
5/16/2022:
Company: OKYO Pharma Limited (OKYO)
Shares Offered: 625,000
More: offering details »
5/17/2022:
Company: European Wax Center, Inc. (EWCZ)
Shares Offered: 4,500,000
More: offering details »
5/23/2022:
Company: The Singing Machine Company, Inc. (SMDM)
Shares Offered: 1,000,000
More: offering details »
5/25/2022:
Company: Agree Realty Corporation (ADC)
Shares Offered: 5,000,000
More: offering details »
5/26/2022:
Company: ClearSign Technologies Corporation (CLIR)
Shares Offered: 3,640,000
More: offering details »
6/1/2022:
Company: Blue Owl Capital Inc. (OWL)
Shares Offered: 10,698,180
More: offering details »
6/2/2022:
Company: Bit Origin Limited (BTOG)
Shares Offered: 9,803,922
More: offering details »
6/2/2022:
Company: TC BioPharm (Holdings) PLC (TCBP)
Shares Offered: 10,000,000
More: offering details »
6/7/2022:
Company: Wintrust Financial Corporation (WTFC)
Shares Offered: 3,000,000
More: offering details »
6/8/2022:
Company: Oxford Lane Capital Corp. (OXLC)
Shares Offered: 2,400,000
More: offering details »
6/14/2022:
Company: Day One Biopharmaceuticals, Inc. (DAWN)
Shares Offered: 10,000,000
More: offering details »
6/14/2022:
Company: VectivBio Holding AG (VECT)
Shares Offered: 5,715,000
More: offering details »
6/15/2022:
Company: Arcellx, Inc. (ACLX)
Shares Offered: 7,000,000
More: offering details »
6/23/2022:
Company: BioSig Technologies, Inc. (BGSM)
Shares Offered: 4,666,667
More: offering details »
6/24/2022:
Company: Quotient Limited (QTNT)
Shares Offered: 66,666,667
More: offering details »
6/27/2022:
Company: Tuya Inc. (TUYA)
Shares Offered: 7,300,000
More: offering details »
6/28/2022:
Company: Gaming and Leisure Properties, Inc. (GLPI)
Shares Offered: 6,900,000
More: offering details »
6/29/2022:
Company: Verrica Pharmaceuticals Inc. (VRCA)
Shares Offered: 12,000,000
More: offering details »
 Free VRCA Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Buy (3.20 out of 4) 27th percentile
(ranked lower than approx. 73% of all stocks covered)
Analysts' Target Price: VRCA Stock Forecast Based on Zacks ABR data; powered by Xignite |
